Media stories about Charles River Laboratories International (NYSE:CRL) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Charles River Laboratories International earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.6715540853285 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of equities analysts have recently commented on CRL shares. Citigroup Inc. reiterated a “neutral” rating and issued a $104.00 price objective (up from $90.00) on shares of Charles River Laboratories International in a research note on Thursday, May 11th. Barclays PLC set a $90.00 price objective on Charles River Laboratories International and gave the stock a “hold” rating in a research note on Saturday, May 13th. Credit Suisse Group reiterated a “neutral” rating and issued a $95.00 price objective (up from $89.00) on shares of Charles River Laboratories International in a research note on Tuesday, June 6th. Jefferies Group LLC reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, June 14th. Finally, BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $98.65.

Charles River Laboratories International (CRL) opened at 108.22 on Friday. The company has a market capitalization of $5.15 billion, a price-to-earnings ratio of 28.52 and a beta of 0.98. The company’s 50-day moving average price is $101.06 and its 200 day moving average price is $94.04. Charles River Laboratories International has a 52 week low of $67.20 and a 52 week high of $109.38.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company had revenue of $469.13 million for the quarter, compared to analysts’ expectations of $458.25 million. During the same period last year, the firm earned $1.20 earnings per share. The business’s revenue for the quarter was up 8.1% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International will post $5.10 EPS for the current year.

Charles River Laboratories International declared that its Board of Directors has approved a stock buyback program on Wednesday, May 10th that allows the company to buyback $150.00 million in outstanding shares. This buyback authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

In other news, insider Davide Molho sold 10,948 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total transaction of $1,094,800.00. Following the transaction, the insider now directly owns 27,497 shares of the company’s stock, valued at $2,749,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Ross Smith sold 2,552 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total transaction of $171,239.20. Following the transaction, the insider now directly owns 11,671 shares in the company, valued at $783,124.10. The disclosure for this sale can be found here. Insiders have sold 74,945 shares of company stock worth $7,398,279 over the last ninety days. Insiders own 2.20% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Charles River Laboratories International (CRL) Earns News Impact Score of 0.16” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://theolympiareport.com/2017/09/03/charles-river-laboratories-international-crl-earns-news-impact-score-of-0-16.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.